Theolytics

All Fund articles Fund PR Portfolio articles Portfolio PR

Theolytics

Theolytics Relocates to State-of-the-Art Facility at ARC Oxford to Drive Development of THEO-260 and Other Novel Oncolytic Immunotherapies

2026.07.162026.07.16 / Oxford UK, July 14th, 2026. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, announces that it has relocated to new, state-of-the-art facilitie ...

Theolytics

Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer

2026.04.282026.05.18 / OCTOPOD-IP is being conducted to investigate intraperitoneal (IP) administration of THEO-260 in women with advanced platinum-resistant ovarian cancer Recruitment on track in OCTOPOD-IV, a Phase 1 ...

Theolytics

Theolytics Awarded €8 million in Horizon Europe 2025 Grant Funding to Advance Phase 2 Study of THEO-260 in Ovarian Cancer

2026.03.052026.03.05 / Pending final negotiation, grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancer Competitive funding award highlights Theol ...

Theolytics

Theolytics to Present Ongoing Phase I/IIa OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer at ESMO 2025

2025.10.132026.03.05 / THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in stromal rich tumours UK clinical t ...

Theolytics

Theolytics Appoints Experienced Medical Oncologist Matilde Saggese, MD, as Chief Medical Officer

2025.10.072026.03.05 / Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260 THEO-260, is currently being investigated in patients with platinum-resistant ovaria ...

Maximizing value when developing oncolytic viral therapy

2025.04.012025.04.30 / As the new CEO for Theolytics, David Apelian aims to take full advantage of the first clinical studies for the company’s lead product. The UK-based biotech has a whole potential platform for creating ...

Theolytics Appoints David Apelian MD, PhD, MBA as CEO

2024.12.172025.04.30 / David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics Dr Apelian joins as the company advances its f ...

Theolytics

Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer

2024.11.192026.03.05 / THEO-260 lyses cancer cells and cancer associated fibroblasts whilst alleviating immune suppression in preclinical studies. THEO-260 is a mechanistically novel oncolytic immunotherapy developed to ...

Evolving to the next phase of viral therapy development

2024.05.012024.05.13 / UK-based Theolytics is about to begin the first clinical trials for one of its cancer-fighting viruses. It’s a major step for any biotech company, often reached only after years of adjusting and read ...

Theolytics

Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics

2024.04.172026.03.05 / Sound Bioventures joins strong international syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford New funding enables Theolyt ...